Clene (CLNN) Projected to Post Earnings on Monday

Clene (NASDAQ:CLNN) is projected to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Clene to post earnings of ($0.74) per share and revenue of $0.0260 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 9:30 AM ET.

Clene (NASDAQ:CLNN) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. On average, analysts expect Clene to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Clene Price Performance

Shares of NASDAQ:CLNN opened at $5.72 on Monday. The business’s 50 day simple moving average is $4.98 and its 200 day simple moving average is $6.72. Clene has a 1 year low of $2.28 and a 1 year high of $13.50. The company has a market capitalization of $62.06 million, a P/E ratio of -2.20 and a beta of 0.62.

Insiders Place Their Bets

In related news, major shareholder Chidozie Ugwumba sold 15,284 shares of the firm’s stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $4.32, for a total transaction of $66,026.88. Following the completion of the transaction, the insider directly owned 565,045 shares of the company’s stock, valued at $2,440,994.40. This trade represents a 2.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 283,174 shares of company stock valued at $1,518,665 in the last three months. Corporate insiders own 35.30% of the company’s stock.

Institutional Investors Weigh In On Clene

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of Clene in the second quarter valued at about $47,000. State Street Corp lifted its stake in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after acquiring an additional 17,300 shares during the period. PEAK6 LLC bought a new stake in Clene in the fourth quarter valued at approximately $294,000. Geode Capital Management LLC boosted its holdings in Clene by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after acquiring an additional 6,090 shares during the last quarter. Finally, Ensign Peak Advisors Inc increased its position in Clene by 668.6% during the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after purchasing an additional 99,481 shares during the period. Institutional investors own 23.28% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. UBS Group reiterated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price target on shares of Clene in a research note on Thursday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $48.00 price objective on shares of Clene in a research report on Friday. Finally, Benchmark reiterated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).